Avraham Raz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11966733/publications.pdf

Version: 2024-02-01

24978 32761 11,307 111 57 100 citations h-index g-index papers 112 112 112 7673 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Galectins: A family of animal \hat{l}^2 -galactoside-binding lectins. Cell, 1994, 76, 597-598.	13.5	1,150
2	Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature, 1984, 312, 646-649.	13.7	768
3	Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis. American Journal of Pathology, 2000, 156, 899-909.	1.9	402
4	Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin. Journal of the National Cancer Institute, 2002, 94, 1854-1862.	3.0	368
5	Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer and Metastasis Reviews, 1987, 6, 433-452.	2.7	297
6	CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Research, 2003, 63, 8302-11.	0.4	280
7	Galectin-3 Translocates to the Perinuclear Membranes and Inhibits Cytochrome c Release from the Mitochondria. Journal of Biological Chemistry, 2002, 277, 15819-15827.	1.6	270
8	Galectin-3 and metastasis. Glycoconjugate Journal, 2002, 19, 543-549.	1.4	268
9	On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer and Metastasis Reviews, 2001, 20, 245-277.	2.7	255
10	Galectin-3 Is a Novel Substrate for Human Matrix Metalloproteinases-2 and -9. Biochemistry, 1994, 33, 14109-14114.	1.2	251
11	Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydrate Research, 2009, 344, 1788-1791.	1.1	248
12	Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest. Journal of Biological Chemistry, 2002, 277, 6852-6857.	1.6	209
13	Galectin-3, a Novel Binding Partner of β-Catenin. Cancer Research, 2004, 64, 6363-6367.	0.4	206
14	Proteases, Extracellular Matrix, and Cancer. American Journal of Pathology, 2004, 164, 1131-1139.	1.9	202
15	Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer, 1995, 75, 2818-2826.	2.0	199
16	Nuclear Export of Phosphorylated Galectin-3 Regulates Its Antiapoptotic Activity in Response to Chemotherapeutic Drugs. Molecular and Cellular Biology, 2004, 24, 4395-4406.	1.1	195
17	Galectin Binding to Mgat5-Modified N-Glycans Regulates Fibronectin Matrix Remodeling in Tumor Cells. Molecular and Cellular Biology, 2006, 26, 3181-3193.	1.1	185
18	Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin. Journal of the National Cancer Institute, 1992, 84, 438-442.	3.0	178

#	Article	IF	Citations
19	Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. International Journal of Cancer, 1990, 46, 871-877.	2.3	174
20	Galectin-3 Stimulates Cell Proliferation. Experimental Cell Research, 1998, 245, 294-302.	1.2	168
21	Galectin-3 in angiogenesis and metastasis. Glycobiology, 2014, 24, 886-891.	1.3	167
22	Metastasis of human colon cancer is altered by modifying expression of the \hat{l}^2 -galactoside-binding protein galectin 3. Gastroenterology, 1998, 115, 287-296.	0.6	162
23	Mechanical Entrapment Is Insufficient and Intercellular Adhesion Is Essential for Metastatic Cell Arrest in Distant Organs. Neoplasia, 2005, 7, 522-527.	2.3	160
24	Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer, 1997, 80, 776-787.	2.0	155
25	Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents. Trends in Molecular Medicine, 2002, 8, 187-192.	3.5	147
26	Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms., 1999, 85, 2475-2484.		146
27	The role of galectin-3 in cancer drug resistance. Drug Resistance Updates, 2007, 10, 101-108.	6.5	129
28	Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene, 2002, 21, 8001-8010.	2.6	128
29	Implication of Galectin-3 in Wnt Signaling. Cancer Research, 2005, 65, 3535-3537.	0.4	126
30	Galectin-3 Inhibits Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis by Activating Akt in Human Bladder Carcinoma Cells. Cancer Research, 2005, 65, 7546-7553.	0.4	118
31	Galectin-3 Regulates Mitochondrial Stability and Antiapoptotic Function in Response to Anticancer Drug in Prostate Cancer. Cancer Research, 2006, 66, 3114-3119.	0.4	114
32	Galectin-3 Protects Human Breast Carcinoma Cells against Nitric Oxide-Induced Apoptosis. American Journal of Pathology, 2001, 159, 1055-1060.	1.9	113
33	Galectin-3 in apoptosis, a novel therapeutic target. Journal of Bioenergetics and Biomembranes, 2007, 39, 79-84.	1.0	108
34	Regulation of Tumor Progression by Extracellular Galectin-3. Cancer Microenvironment, 2008, 1, 43-51.	3.1	106
35	Transformation-related changes in the expression of endogenous cell lectins. International Journal of Cancer, 1987, 39, 353-360.	2.3	104
36	Lectins in Cancer Cells. Annals of the New York Academy of Sciences, 1988, 551, 385-398.	1.8	101

#	Article	IF	Citations
37	Galectin-3 Regulates a Molecular Switch from N-Ras to K-Ras Usage in Human Breast Carcinoma Cells. Cancer Research, 2005, 65, 7292-7300.	0.4	100
38	Galectin-3 and cancer stemness. Glycobiology, 2018, 28, 172-181.	1.3	100
39	Phosphorylation of the \hat{I}^2 -Galactoside-binding Protein Galectin-3 Modulates Binding to Its Ligands. Journal of Biological Chemistry, 2000, 275, 36311-36315.	1.6	96
40	Cleavage of galectinâ€3 by matrix metalloproteases induces angiogenesis in breast cancer. International Journal of Cancer, 2010, 127, 2530-2541.	2.3	92
41	Structure-function relationship of a recombinant human galactoside-binding protein. Biochemistry, 1993, 32, 4455-4460.	1.2	90
42	Galectin-3 as a Potential Therapeutic Target in Tumors Arising from Malignant Endothelia. Neoplasia, 2007, 9, 662-670.	2.3	89
43	Alterations in Galectin-3 Expression and Distribution Correlate with Breast Cancer Progression. American Journal of Pathology, 2004, 165, 1931-1941.	1.9	88
44	Galectin-3 Cleavage: A Novel Surrogate Marker for Matrix Metalloproteinase Activity in Growing Breast Cancers. Cancer Research, 2007, 67, 11760-11768.	0.4	88
45	Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma. Clinical Cancer Research, 2006, 12, 6709-6715.	3.2	84
46	Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 22-36.	0.9	81
47	Malignant transformation of thyroid follicular cells by galectin-3. Cancer Letters, 2003, 195, 111-119.	3.2	79
48	Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin. Cancer Research, 2012, 72, 5757-5766.	0.4	79
49	Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis. Clinical Cancer Research, 2004, 10, 7775-7784.	3.2	77
50	Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-hete. International Journal of Cancer, 1993, 55, 1003-1010.	2.3	71
51	Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer and Metastasis Reviews, 2007, 26, 605-610.	2.7	71
52	Galectin-3 Inhibits Osteoblast Differentiation through Notch Signaling. Neoplasia, 2014, 16, 939-949.	2.3	71
53	Pleiotropic Effects of Modified Citrus Pectin. Nutrients, 2019, 11, 2619.	1.7	68
54	Cell-contact and-architecture of malignant cells and their relationship to metastasis. Cancer and Metastasis Reviews, 1987, 6, 3-21.	2.7	67

#	Article	IF	CITATIONS
55	Differential expression of cell adhesion molecules in variants of K1735 melanoma cells differing in metastatic capacity. International Journal of Cancer, 1989, 43, 709-712.	2.3	66
56	Inhibition of breast tumor growth and angiogenesis by a medicinal herb:Ocimum gratissimum. International Journal of Cancer, 2007, 121, 884-894.	2.3	63
57	Effects of DNA Methylation on Galectin-3 Expression in Pituitary Tumors. Cancer Research, 2005, 65, 1136-1140.	0.4	62
58	Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis. Cancer Research, 2016, 76, 1391-1402.	0.4	62
59	Nuclear transport of galectin-3 and its therapeutic implications. Seminars in Cancer Biology, 2014, 27, 30-38.	4.3	60
60	Cell shape modulation alters glycosylation of a metastatic melanoma cell-surface antigen. International Journal of Cancer, 1987, 40, 396-402.	2.3	58
61	Racial Disparity in Breast Cancer and Functional Germ Line Mutation in Galectin-3 (rs4644): A Pilot Study. Cancer Research, 2008, 68, 10045-10050.	0.4	58
62	Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. Oncotarget, 2014, 5, 2077-2084.	0.8	54
63	Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget, 2013, 4, 542-549.	0.8	53
64	Ripening-induced chemical modifications of papaya pectin inhibit cancer cell proliferation. Scientific Reports, 2017, 7, 16564.	1.6	47
65	Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget, 2014, 5, 9992-10001.	0.8	45
66	Phosphorylation of Galectin-3 Contributes to Malignant Transformation of Human Epithelial Cells via Modulation of Unique Sets of Genes. Cancer Research, 2005, 65, 10767-10775.	0.4	43
67	On the Role of Galectins in Signal Transduction. Methods in Enzymology, 2006, 417, 273-289.	0.4	42
68	Importin-mediated Nuclear Translocation of Galectin-3. Journal of Biological Chemistry, 2006, 281, 39649-39659.	1.6	41
69	Phosphorylated Galectin-3 Mediates Tumor Necrosis Factor-related Apoptosis-inducing Ligand Signaling by Regulating Phosphatase and Tensin Homologue Deleted on Chromosome 10 in Human Breast Carcinoma Cells. Journal of Biological Chemistry, 2007, 282, 21337-21348.	1.6	41
70	Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Research and Treatment, 1998, 49, 171-183.	1.1	40
71	Tyrosine-phosphorylated Galectin-3 Protein Is Resistant to Prostate-specific Antigen (PSA) Cleavage. Journal of Biological Chemistry, 2012, 287, 5192-5198.	1.6	38
72	Carbohydrate-recognition and angiogenesis. Cancer and Metastasis Reviews, 2000, 19, 51-57.	2.7	35

#	Article	IF	Citations
73	Galectin-3 Mediates Cross-Talk between K-Ras and Let-7c Tumor Suppressor microRNA. PLoS ONE, 2011, 6, e27490.	1.1	35
74	Migration and proliferation of cancer cells in culture are differentially affected by molecular size of modified citrus pectin. Carbohydrate Polymers, 2019, 211, 141-151.	5.1	33
75	Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. International Journal of Cancer, 1995, 63, 100-105.	2.3	32
76	Galectin-3: A novel substrate for c-Abl kinase. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 1198-1205.	1.9	27
77	Multivalent scaffolds induce galectin-3 aggregation into nanoparticles. Beilstein Journal of Organic Chemistry, 2014, 10, 1570-1577.	1.3	26
78	Growth control and cell spreading: Differential response in preneoplastic and in metastatic cell variants. International Journal of Cancer, 1982, 29, 711-715.	2.3	24
79	Galectin-3 Binding and Metastasis. Methods in Molecular Biology, 2012, 878, 251-266.	0.4	24
80	Galectin-3 N-terminal tail prolines modulate cell activity and glycan-mediated oligomerization/phase separation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118,	3.3	24
81	Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management. Cancer and Metastasis Reviews, 2016, 35, 333-346.	2.7	23
82	Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget, 2015, 6, 19592-19604.	0.8	23
83	Tumor cell motility and metastasis. Pathology and Oncology Research, 1997, 3, 230-254.	0.9	21
84	Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization., 1998, 76, 120-128.		21
85	Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 985-993.	1.9	21
86	Glycodendrimers and Modified ELISAs: Tools to Elucidate Multivalent Interactions of Galectins 1 and 3. Molecules, 2015, 20, 7059-7096.	1.7	21
87	Galectin-3 in Tumor Metastasis Trends in Glycoscience and Glycotechnology, 1997, 9, 69-75.	0.0	20
88	Galectins and urological cancer. Journal of Cellular Biochemistry, 2004, 91, 118-124.	1.2	19
89	Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. Oncotarget, 2016, 7, 82266-82272.	0.8	18
90	The establishment and characterization of a new balb/c angiosarcoma tumor system. International Journal of Cancer, 1985, 36, 261-272.	2.3	17

#	Article	IF	Citations
91	Autocrine motility factor and the extracellular matrix. II. Degradation or remodeling of substratum components directs the motile response of tumor cells., 1998, 76, 129-135.		17
92	The Complex Biological Effects of Pectin: Galectin-3 Targeting as Potential Human Health Improvement?. Biomolecules, 2022, 12, 289.	1.8	15
93	Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms., 1999, 85, 2475.		13
94	Cancer Self-Defense: An Immune Stealth. Cancer Research, 2017, 77, 5441-5444.	0.4	11
95	GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling. Molecular and Cellular Biology, 2019, 39, .	1.1	11
96	Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. , 1997, 80, 776.		10
97	Actin Organization, Cell Motility, and Metastasis. Advances in Experimental Medicine and Biology, 1988, 233, 227-233.	0.8	9
98	Autocrine motility factor and its receptor expression in musculoskeletal tumors. Journal of Bone Oncology, 2020, 24, 100318.	1.0	8
99	The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II. Oncotarget, 2017, 8, 17643-17650.	0.8	8
100	The ubiquitin specific protease USP34 protects the ubiquitin ligase gp78 from proteasomal degradation. Biochemical and Biophysical Research Communications, 2019, 509, 348-353.	1.0	5
101	Galectin-3: an immune checkpoint target for musculoskeletal tumor patients. Cancer and Metastasis Reviews, 2021, 40, 297-302.	2.7	4
102	Amplification of autocrine motility factor and its receptor in multiple myeloma and other musculoskeletal tumors. Journal of Bone Oncology, 2020, 23, 100308.	1.0	3
103	MYH9 binds to dNTPs via deoxyribose moiety and plays an important role in DNA synthesis. Oncotarget, 2022, 13, 534-550.	0.8	3
104	Professor Lina M. Obeid (1955–2019). Cancer and Metastasis Reviews, 2019, 38, 839-839.	2.7	2
105	Adhesive Properties of Metastasizing Tumour Cells. Novartis Foundation Symposium, 1988, 141, 109-122.	1.2	2
106	Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization., 1998, 76, 120.		1
107	On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. , 2002, , 109-141.		0
108	Sugar recognition and metastasis: From birth of a research field to the clinic. Cancer Biology and Therapy, 2005, 4, 679-681.	1.5	0

#	Article	IF	CITATIONS
109	Dr. Fidler, I.J.â€"Forty years of metastasis research. Cancer and Metastasis Reviews, 2007, 26, 357-358.	2.7	0
110	Work accomplishments—Isaiah J. Fidler. Cancer and Metastasis Reviews, 2007, 26, 353-355.	2.7	0
111	On the Role of Galectin-3 in Cancer Metastasis: From the Bench to the Clinic and Back. Nihon Kikan Shokudoka Gakkai Kaiho, 2008, 59, 91-91.	0.0	0